GSK Can Finally Claim A Turnaround Thanks To Arexvy’s Blockbuster Launch

GSK’s RSV vaccine Arexvy is a clear early winner against Pfizer’s rival, prompting analysts to finally turn optimistic about the company’s long-term prospects.

After years in the doldrums, GSK finally looks on course to complete a turnaround in its business.

The product which sealed this reversal of fortune is new respiratory syncytial virus vaccine Arexvy – it has reached $1bn blockbuster sales from its first six

Key Takeaways

Arexvy has defied fears about vaccine hesitancy in the US, becoming an ‘overnight’ blockbuster
The success could be the catalyst for growing confidence in GSK, after years of investor dissatisfaction at its performance

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

06 May 2025

• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Lilly’s Ricks Urges Trump To Pick Tax Incentives Over Tariffs

02 May 2025

• By Alaric DeArment

On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.

Transient FY26 For Syngene But Momentum In China +1 Projects

02 May 2025

• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.